康惠制药：上半年亏损4020.36万元

Core Viewpoint - Kanghui Pharmaceutical (603139) reported a decline in revenue and a significant net loss for the first half of 2025, indicating challenges in its operational performance and market conditions [1] Financial Performance - The company achieved an operating revenue of 248 million yuan, representing a year-on-year decrease of 6.83% [1] - The net profit attributable to shareholders was -40.20 million yuan, with a basic earnings per share of -0.4 yuan [1] Reasons for Performance Decline - The significant loss was primarily due to: 1. High depreciation and financing loan interest expenses at the subsidiary Shaanxi Youbang, coupled with unfavorable market supply and demand dynamics, leading to substantial losses in the first half of 2025 [1] 2. The subsidiary Chunsheng Pharmaceutical experienced a notable business decline due to adverse market conditions, resulting in considerable losses [1] 3. Increased costs and expenses at the parent company level [1]